3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Neuroendocrine Tumors
208
Multiple Endocrine Neoplasia Type 1
130
Thyroid Cancer, Papillary
78
Pituitary Neoplasms
70
Thyroid Neoplasms
59
Pheochromocytoma
55
Carcinoma, Neuroendocrine
49
Neoplasms
48
Carcinoid Tumor
48
Carcinoma, Medullary
35
Adrenocortical Carcinoma
35
Adenocarcinoma, Follicular
34
Pancreatic Neoplasms
33
Thyroid Carcinoma, Anaplastic
30
Neoplasm Metastasis
27
Carcinoma, Non-Small-Cell Lung
27
Insulinoma
26
Breast Neoplasms
25
Paraganglioma
24
Melanoma
23
Colorectal Neoplasms
23
Colonic Neoplasms
23
Carcinoma, Renal Cell
23
Adenoma, Islet Cell
23
Somatostatinoma
22
Adrenal Gland Neoplasms
22
Sarcoma
21
Carcinoma, Islet Cell
21
Prostatic Neoplasms
20
Glucagonoma
19
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Endocrine
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled